世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

CANADA SURGICAL SITE INFECTION CONTROL MARKET FORECAST 2024-2032

CANADA SURGICAL SITE INFECTION CONTROL MARKET FORECAST 2024-2032


KEY FINDINGS The Canada surgical site infection control market is predicted to grow with a CAGR of 3.57% during the projection period of 2024-2032. The market was valued at $160.90 million in 2023... もっと見る

 

 

出版社 出版年月 電子版価格 納期 ページ数 言語
Inkwood Research
インクウッドリサーチ
2024年11月7日 US$1,100
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
2-3営業日以内 134 英語

 

Summary

KEY FINDINGS
The Canada surgical site infection control market is predicted to grow with a CAGR of 3.57% during the projection period of 2024-2032. The market was valued at $160.90 million in 2023 and is expected to reach $224.01 million by 2032. The Canada surgical site infection control market is driven by the increasing prevalence of surgical site infections (SSIs) and the resulting emphasis on patient safety and infection prevention.
MARKET INSIGHTS
Key factors include advancements in aseptic techniques, government initiatives, and the implementation of standardized SSI surveillance systems to monitor and reduce infection rates. Additionally, the rising number of surgeries, particularly among the aging population, and the focus on improving healthcare outcomes are boosting the demand for SSI control products and solutions in Canada.
The Canadian healthcare system continues to face significant challenges associated with surgical site infections (SSIs). In fact, according to the Canadian Patient Safety Institute (CPSI), SSIs are the most common type of healthcare-associated infection among surgical patients, with infections linked to 77% of patient deaths in this group. Despite advancements in aseptic techniques, antibiotic prophylaxis, and minimally invasive surgical procedures, healthcare-associated infections (HAIs) remain a persistent issue, complicating the recovery of many surgical patients.
The Centers for Disease Control (CDC) highlights that while there have been improvements in infection control practices, including enhanced operating room ventilation and sterilization methods, SSIs still contribute substantially to morbidity, prolonged hospital stays, and mortality in Canada. In response to these challenges, the ‘Safer Healthcare Now!’ initiative introduced the SSI Getting Started Kit in 2005, aimed at promoting standardized SSI prevention processes across healthcare facilities.
Since its introduction, 145 healthcare organizations throughout Canada have self-reported data on SSI prevention measures. This initiative has played a key role in improving surgical care safety, leading to a notable decline in SSI rates for clean and clean-contaminated surgeries from 2005 to 2021. These ongoing prevention efforts are a major driver of the SSI control market in Canada, as healthcare providers continue to prioritize infection prevention and patient safety to achieve better surgical outcomes.
SEGMENTATION ANALYSIS
The Canada surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The end-user segment is further classified into hospitals and ambulatory surgical centers. Surgical site infections (SSIs) account for approximately 15% of all hospital-acquired infections and are the most prevalent type of nosocomial infection among surgical patients. These infections significantly impact patient outcomes, leading to extended postoperative hospital stays, increased healthcare costs, higher rates of hospital readmission, and compromised health outcomes.
Hospitals play a crucial role as a key end-user segment in the surgical site infection control market, given their responsibility for patient care and infection prevention. As primary centers for surgical procedures, hospitals are heavily invested in implementing comprehensive infection control measures, including the adoption of advanced antiseptics, wound care products, and infection monitoring systems. The increasing focus on patient safety, adherence to stringent healthcare regulations, and the rising number of surgeries performed are driving hospitals to prioritize effective SSI prevention strategies, thereby fueling the demand for SSI control products and solutions in this segment.
COMPETITIVE INSIGHTS
Some of the prominent companies operating in the Canada surgical site infection control market are 3M Company, Ansell Ltd, Becton, Dickinson and Company (BD), etc.
Ansell is a leading global provider of protection solutions, specializing in the design, development, and manufacturing of a wide range of products, including surgical and examination gloves, industrial and household gloves, protective clothing, and condoms. The company operates through four key business segments: industrial, medical, single-use, and sexual wellness.
With a primary focus on safety, Ansell aims to deliver advanced solutions and technologies to address the challenges faced by industrial workers and healthcare professionals, ensuring their safety and protection in both professional and personal settings. Ansell has established a strong global presence, with offices and manufacturing facilities in 52 countries worldwide. The company provides protection solutions to both industrial and healthcare sectors, emphasizing innovation and value-added services to enhance its offerings.


ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
2.6.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
2.6.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN GERIATRIC POPULATION
3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
3.2.3. RISING USE OF OUTPATIENT TREATMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING RATE OF SURGICAL PROCEDURES
4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. MARKET CONCENTRATION ANALYSIS
5. MARKET BY PROCEDURE
5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES
6. MARKET BY TYPE OF INFECTION
6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS
8. MARKET BY PRODUCT
8.1. DISINFECTANTS
8.1.1. SKIN DISINFECTANTS
8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PARTNERSHIPS & AGREEMENTS
9.1.3. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. 3M COMPANY
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCTS
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. ANSELL LTD
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCTS
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. BECTON, DICKINSON AND COMPANY
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCTS
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. JOHNSON & JOHNSON
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCTS
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. KIMBERLY-CLARK
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCTS
9.2.5.3. STRENGTHS & CHALLENGES

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(surgical)の最新刊レポート


よくあるご質問


Inkwood Research社はどのような調査会社ですか?


Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/01/31 10:26

155.43 円

161.86 円

195.69 円

ページTOPに戻る